Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Recombinant Factor VIIa Treatment for Massive Hemorrhage in Patients with Multiple Traumas

  • Koh, Young Rae (Department of Laboratory Medicine, Pusan National University School of Medicine) ;
  • Cho, Suck Ju (Department of Emergency Medicine, Pusan National University School of Medicine) ;
  • Yeom, Seok Ran (Department of Emergency Medicine, Pusan National University School of Medicine) ;
  • Chang, Chulhun L. (Department of Laboratory Medicine, Pusan National University School of Medicine) ;
  • Lee, Eun Yup (Department of Laboratory Medicine, Pusan National University School of Medicine) ;
  • Son, Han Chul (Department of Laboratory Medicine, Pusan National University School of Medicine) ;
  • Kim, Hyung Hoi (Department of Laboratory Medicine, Pusan National University School of Medicine)
  • Published : 2012.03.01
⟨ Previous Next ⟩

Abstract

Background: Recent studies and case reports have shown that recombinant factor VIIa (rFVIIa) treatment is effective for reversing coagulopathy and reducing blood transfusion requirements in trauma patients with life-threatening hemorrhage. The purpose of this study is to evaluate the effect of rFVIIa treatment on clinical outcomes and cost effectiveness in trauma patients. Methods: Between January 2007 and December 2010, we reviewed the medical records of patients who were treated with rFVIIa (N=18) or without rFVIIa (N=36) for life-threatening hemorrhage due to multiple traumas at the Emergency Department of Pusan National University Hospital in Busan, Korea. We reviewed patient demographics, baseline characteristics, initial vital signs, laboratory test results, and number of units transfused, and then analyzed clinical outcomes and 24-hr and 30-day mortality rates. Thromboembolic events were monitored in all patients. Transfusion costs and hospital stay costs were also calculated. Results: In the rFVIIa-treated group, laboratory test results and clinical outcomes improved, and the 24-hr mortality rate decreased compared to that in the untreated group; however, 30-day mortality rate did not differ between the groups. Thromboembolic events did not occur in both groups. Transfusion and hospital stay costs in the rFVIIa-treated group were cost effective; however, total treatment costs, including the cost of rFVIIa, were not cost effective. Conclusions: In our study, rFVIIa treatment was shown to be helpful as a supplementary drug to improve clinical outcomes and reduce the 24-hr mortality rate, transfusion and hospital stay costs, and transfusion requirements in trauma patients with life-threatening hemorrhage.

Keywords

References

  1. Miller RD. Complications of massive blood transfusions. Anesthesiology 1973;39:82-93. https://doi.org/10.1097/00000542-197307000-00012
  2. Rudolph R and Boyd CR. Massive transfusion: complications and their management. South Med J 1990;83:1065-70. https://doi.org/10.1097/00007611-199009000-00021
  3. Pike AC, Brzozowski AM., Roberts SM, Olsen OH, Persson E. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proc Natl Acad Sci 1999;96:8925-30. https://doi.org/10.1073/pnas.96.16.8925
  4. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000;26:425-32. https://doi.org/10.1055/s-2000-8463
  5. Franchini M. Recombinant factor VIIa: a review on its clinical use. Int J Hematol 2006;83:126-38. https://doi.org/10.1532/IJH97.E0517
  6. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879. https://doi.org/10.1016/S0140-6736(99)05155-7
  7. Goodnough LT and Shander AS. Recombinant factor VIIa: safety and efficacy. Curr Opin Hematol 2007;14:504-9. https://doi.org/10.1097/MOH.0b013e32826388c3
  8. Joo YM, Yeom SR, Ryu JH, Jeong JW, Kim YI, Min MK, et al. Successful hemostasis by the use of recombinant factor VIIa in uncontrolled active hemorrhage of multiple trauma patients. J Korean Soc Emerg Med 2011;22:22-9.
  9. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-8. https://doi.org/10.1097/00005373-200109000-00002
  10. Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J Clin Anesth 2003;15:184-8. https://doi.org/10.1016/S0952-8180(03)00034-5
  11. Mayo A, Misgav M, Kluger Y, Greenberg R, Pauzner D, Klausner J, et al. Recombinant activated factor VII (NovoSeven) : addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang 2004;87:34-40. https://doi.org/10.1111/j.1423-0410.2004.00533.x
  12. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004;44:1325-31. https://doi.org/10.1111/j.1537-2995.2004.04052.x
  13. Loudon B and Smith MP. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation. Intern Med J 2005;35:463-7. https://doi.org/10.1111/j.1445-5994.2005.00878.x
  14. Grounds RM, Seebach C, Knothe C, Paluszkiewicz P, Smith TS, Kasal E, et al. Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry. J Intensive Care Med 2006;21:27-39. https://doi.org/10.1177/0885066605285024
  15. Rizoli SB, Nascimento B Jr, Osman F, Netto FS, Kiss A, Callum J, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma 2006;61:1419-25. https://doi.org/10.1097/01.ta.0000243045.56579.74
  16. Cameron P, Philips L, Balogh Z, Joseph A, Pearce A, Parr M, et al. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry. Injury 2007;38:1030-8. https://doi.org/10.1016/j.injury.2007.05.003
  17. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8-15. https://doi.org/10.1097/01.TA.0000171453.37949.B7
  18. Rizoli SB, Boffard KD, Riou B, Warren B, Lau P, Kluger Y, et al. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care 2006;10:R178. https://doi.org/10.1186/cc5133
  19. Martinowitz U and Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli multidisciplinary rFVIIa task force. J Thromb Haemost 2005;3:640-8. https://doi.org/10.1111/j.1538-7836.2005.01203.x
  20. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Crit Care 2006;10:R120. https://doi.org/10.1186/cc5026
  21. Klitgaard T, Tabanera y Palacios R, Boffard KD, Iau PT, Warren B, Rizoli S, et al. Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding. Crit Care 2006;10:R104. https://doi.org/10.1186/cc4977
  22. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011;154:529-40. https://doi.org/10.7326/0003-4819-154-8-201104190-00004
  23. Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2011;16:CD005011.

Cited by

  1. Emergency postpartum hysterectomy: incidence, trends, indications, and complications vol.2, pp.2, 2012, https://doi.org/10.14390/jsshp.2.88